×

23andMe

What
Low-cost DNA analysis service providing individuals with access to personalized genetic data to inform health care decisions.

Disrupting
Traditional health-care industry model of reactive patient care.

Source: 23 and Me

Headquarters: Mountain View, Calif.
CEO: Anne Wojcicki
Year Founded: 2006
Number of Employees: 92
Funding: $126.4 million
Key Investors: Google Ventures, MPM Capital, New Enterprise Associates, Sergey Brin, Esther Dyson, Yuri Milner, Johnson & Johnson Development Corp., the Roche Venture Fund (Genentech)

Vital Stats

  • Personal Genome Service is $99 (and requires a little of your saliva)
  • Has more than 250,000 genotyped customers
  • Goal is 1 million genotyped customers by the end of 2013—the 1 million threshhold is the key to larger genetic discoveries more quickly
  • Name refers to the 23 pairs of chromosomes that make up person's genome
  • Has collected 100 million phenotypic data points from surveys to fuel genetic research effort
  • Collects 2 million survey responses online each week
  • Jimmy Buffett and Warren Buffett, both of them customers, are not closely related, according to DNA analysis
  • CEO is the wife of Sergey Brin

On Disruption

"Disruptions make people uncomfortable but bring about needed change. I believe 23andMe will disrupt healthcare and fuel genetic discovery." -Anne Wojcicki, CEO and Co-Founder

Tech

Latest Special Reports

  • Take an in-depth look at the world of modern medicine - examining the treatments, companies and people making a difference in the way we treat illness and injuries today, and laying the foundation for the medical treatments of tomorrow.

  • A trader works on the floor of the New York Stock Exchange.

    Using ETFs investors can now span the globe in their portfolios. It’s now more important than ever to diversify assets.

  • Trading Nation

    Where headlines become opportunities.